Four recommendations are made to address the high costs of cancer therapy: remove coverage mandates from state and federal insurance law, create performance transparency for drug regimens, cap profit margins for administering drugs, and place every patient with a genetic mutation in a clinical trial.
No takes yet. Share an insight, caveat, or question.
Lee N. Newcomer (2016) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: